Phase II A/B Results


Can Ketamine-Assisted Therapy increase abstinence rates in patients with Alcohol Use Disorder following detox?

What is KARE?

  • Four armed Phase II a/b clinical trial for reducing relapse in Alcohol Use Disorder with the NMDA receptor antagonist Ketamine.
  • Funded by the UK State (Medical Research Council)
  • Conducted by University of Exeter
  • Led by Prof. Celia Morgan
  • Rights to KARE exclusively acquired by Awakn Life Sciences in February 2021
  • N=96
  • Published: December 2021 in the American Journal of Psychiatry
  • Full paper can be found here.

KARE Trial Design


KARE Treatment Protocol

The treatment protocol took place over 4 weeks and consisted of 7 therapy sessions of 1.5hrs long each, and three ketamine sessions.




Primary Outcomes

1. KARE therapy significantly increased abstinence over all other groups.
2. Odds ratio of relapse was reduced with the KARE therapy.

Secondary Outcomes

1. Ketamine groups showed increased liver function across several markers.
2. Ketamine groups saw reduced depression and anhedonia (inability to experience pleasure) at 3 months.

Exploratory Analysis 

Heavy drinking days were reduced in the KARE group compared to all other groups.


Ketamine was well tolerated and had a good safety profile, adverse events were predominantly mild and only  reported by 8/96 patients. No serious adverse events happened.

A Qualitative Study of Patients’ Experiences:
“This Is Something That Changed My Life”

In conjunction with the KARE study, a further study was conducted on the qualitative patient outcomes during the trial. This has also been published in Frontiers in Psychiatry, click here for the full paper.


The study aimed to examine participant experiences of ketamine infusions and how these relate to therapeutic mechanisms in a clinical trial setting.


Provided in a supportive and professional environment, ketamine treatment led to a significant change in their relationship with alcohol. Ketamine induced ego dissolution and dissociation were reported to be related to the transformational effects on relationship with alcohol.


Sign Up for Newsletter


301-217 Queen St. W, Toronto, ON, M5V 0R2, Canada

1 Regent Street, Bristol, BS8 4HW, United Kingdom

© 2021 Awakn Life Sciences Corp      |      Privacy Policy      |      Appropriate Use Policy

Back to top Arrow